Catalent to Invest $9 Million to Establish San Diego Clinical Supply Facility

September 5, 2019

The new facility will handle clinical supply management, primary and secondary packaging, complex labeling services, clinical storage, distribution, and drug returns and destruction and will include stability chambers.

Catalent announced on Sept. 5, 2019 that it will invest $9 million into a new clinical supply facility in San Diego, CA. The facility will begin operations in the summer of 2020. 

The new facility will provide clinical supply services to pharmaceutical and biopharmaceutical customers and will specialize in services for early-phase clinical trials while enhancing the company’s OptiForm Total Supply service, which offers customers integrated development, clinical supply manufacturing, and distribution. The facility will also handle clinical supply management, primary and secondary packaging, complex labeling services, clinical storage, distribution, and drug returns and destruction and will include stability chambers.

“This investment supports Catalent’s commitment to offering customers greater flexibility and expanded support for early-phase studies,” said Paul Hegwood, president, clinical supply services, in a company press release. “The facility will allow Catalent to provide superior clinical services throughout the western corridor of the [Unites States] and Canada’s drug development region.”

The facility will join two existing Catalent global centers of excellence in oral dose early-phase development in Somerset, NJ, and Nottingham, UK. 

Source: Catalent